Flabby pharma
31 March 2006

Take Pfizer the world s biggest drugs group runs its balance sheet like a biotech with uncertain prospects. With net cash, slowing growth and a stock that hasn t moved in eight years, Pfizer could easily buy back $50bn in stock.